Nyxoah (NYXH) has released an update.
Nyxoah SA, a Belgian medical technology firm specializing in sleep apnea solutions, has appointed Scott Holstine as Chief Commercial Officer, positioning the company for a strong U.S. launch following expected FDA approval by the end of 2024. With over 26 years of experience in the medical device sector, Holstine’s role will be integral in leading Nyxoah’s commercial strategy and establishing a U.S. commercial team by year-end. The company anticipates that Holstine’s leadership will bolster their mission to simplify sleep for OSA patients with their innovative Genio system.
For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.